large group of patients with all the authorized indications that transition from the reference product Remicade to Remsima does not lead to disease worsening and there is no difference in safety and immunogenicity. [4] [5] [6] In February 2015, Remsima was launched in The Netherlands and other European countries. The continuous cost containment in healthcare will be proven over time with the transition from Remicade to Remsima. Analysis of the effect of open label transition to the biosimilar in the clinic is necessary. However, the transition to the biosimilar seems to be challenging in daily practice 7 and data on the transition are limited. Therefore, we want to investigate the transition from the reference product Remicade to the biosimilar Remsima in patients with rheumatoid arthritis (RA) and psoriatic arthritis (PsA) in daily practice in our Rheumatology and Immunology
Center Reade, Amsterdam, The Netherlands.
| ME THODS

| Patients
All consecutive patients with the clinical diagnosis of RA or PsA, ≥18
years of age treated with infliximab (Remicade) at the Amsterdam Rheumatology and immunology Center Reade were included in this study. Patients were informed by a letter about the transition to the biosimilar Remsima and were subsequently contacted by a nurse or a pharmacist for answering any additional questions they might have and whether they agreed upon the transition. Patients were advised to contact their treating rheumatologist when in doubt.
The communication about the biosimilar was in accordance with the Dutch Association of Hospital Pharmacists (NVZA) by using the NVZA toolbox Biosimilars, which is a practical guide for successful implementation of biosimilars in daily practice. 8 Once agreeing upon the transition, Remsima was administered at the same dosage and frequency as Remicade at the next infusion. If not agreed upon, Remicade was continued. In addition, all patients who were switched from Remicade to Remsima were approached at the day therapy center to fill in a questionnaire. In this qualitative questionnaire, patients were asked to evaluate the information provision process with insufficient, sufficient, reasonable, good or excellent.
In addition, they were asked how they initially gained information about the transition to the biosimilar. This was done by the rheumatology nurses. Patients could evaluate the information provision process.
| Study design and end points
The study was a single center retrospective cohort study. In the pe- 
Demographic features
Age, mean (SD) y 66 (15) 62 (6) 65 (14) Female, n (%) 32 (78) 
| Switching to another TNF inhibitor
As mentioned above, two patients switched to another TNF inhibitor due to inefficacy. This was done 4 and 12 months after the transition to the biosimilar: one patient switched to etanercept and one patient to adalimumab. At the time of switching, both patients had a high DAS28-ESR (4.3 and 3.9). They were using methotrexate at baseline and during the follow up, no changes were made in dosage.
One patient received a corticosteroid injection before switching to adalimumab.
| Returning to reference product Remicade
Restarting Remicade was due to inefficacy according to the patients;
however, this could not be objectified by the rheumatologist. Those three patients switched back to the reference product Remicade between 2 and 5 months after transition; no DAS28-ESR was reported.
All patients were using concomitant methotrexate. After 2 years of follow up, one patient remained on Remicade, one patient stopped therapy due to melanoma skin cancer and one patient switched to abatacept due to increased disease activity. Did not agreed upon the transition
| Patients' perspectives toward information provision
A total of 45 patients who switched to the biosimilar filled in the questionnaire, of which 15 patients scored the information provision as excellent (33%), 24 patients as good (54%), four patients as reasonable (9%) and two patients found the information sufficient (4%) ( Figure 2A) ; there were no patient who scored the information provision with insufficient. The majority of patients were initially informed by nurses and rheumatologists prior to the letter that was send to all patients. In total, 11 patients were initially informed by a rheumatology nurse (26%) and 12 patients by the rheumatologist (26%). Four patients were informed via the letter that was send at first (9%) and three patients gained the information about the transition otherwise (7%). Fifteen patients gave more than 1 answer to the question by whom they were informed initially ( Figure 2B ).
| D ISCUSS I ON
This biosimilar transition study assessed the transition from the reference product Remicade to the biosimilar Remsima in patients with RA
and PsA in daily clinical practice. This study showed that 100% transition from the reference product to the biosimilar seems to be difficult in daily practice. In our population, patients were willing to switch to the biosimilar and 87% of the patients continued Remsima after the transition, yet 7% restarted the reference product Remicade, 4%
switched to another TNF inhibitor due to secondary loss of efficacy and in 2% of the patients Remsima was stopped due to malignancy.
In total 13% of the patients discontinued Remsima at the end of the follow-up period of 2 years. However, other observational studies reported a discontinuation rate of 16%-28%. the substantial discontinuation rate was due to the so-called nocebo effect, which is negative perceptions of the patients toward the treatment which might result in negative outcomes. 7 Moreover, 4% of the patients who continued Remsima in the first place switched to another biologic due to inefficacy. This could be explained by overall effectiveness of TNF blockers. In previous studies, it has been shown that approximately 30% of the patients using TNF blockers fail to achieve a 20% clinical improvement according to the American College of Rheumatology. 11, 12 The lack of efficacy with TNF blockers can be primary or secondary, where there is respectively absence of any clinical response or there is disappearance of an initially promising response. Even after long-term use of infliximab, secondary failure is still a possibility. 13 Another factor that might explain the transition back to Remicade could be due to incorrect causal attribution, which is caused by the awareness of the patients and physicians about the open transition to the biosimilar. In a previous study it was shown that patients' and physicians' perceptions toward the reference product seems to be higher in comparison to the biosimilar in terms of efficacy and safety. 14 This might have potential negative impact on adherence and treatment outcomes. 15, 16 Patient-physician interaction seems to be important in the treatment continuation of patients. 17 In addition, patients' education which can be face-to-face discussion with the physician, and access to a helpline during the transition seems to enhance the acceptance of the biosimilar and reduces the nocebo effect. 18 Therefore, it is important to enhance the awareness and knowledge about the biosimilar among physicians and patients to minimize the nocebo effect.
We demonstrated that patients were satisfied about the pro- The findings of this study are relevant in the light of future implementation of the upcoming biosimilars in daily practice. However, we are aware of the limitations of our study since the data are retrospective and the sample size is relatively small as it was a singlecenter study. We chose not to evaluate the safety, pharmacokinetics and pharmacodynamics of the biosimilar, since those factors have been studied before. 4, 19, 20 We were mainly interested in the transition process of the reference product to the biosimilar in daily practice supposing there is no difference between the reference product and the biosimilar.
| CONCLUSION
In our population, 87% of patients continued Remsima during the follow-up period of approximately 2 years. Two patients switched to another biologic due to secondary loss of efficacy. Only three patients restarted Remicade, while retaining stable DAS28-ESR.
Overall, patients were satisfied about the information provided and this might have contributed to the respectively low discontinuation rates. 
